Royalty Pharma Announces Acquisition of Royalty Rights on Global Sales of Sacituzumab Govitecan (IMMU-132) for $175 million

New York, N.Y and Morris Plains, N.J. - January 8, 2018 – Royalty Pharma and Immunomedics, Inc., (NASDAQ: IMMU) today announced that Immunomedics has agreed to sell tiered, sales-based royalty rights on global net sales of sacituzumab govitecan to Royalty Pharma for $175 million.

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.